Gsa Capital Partners LLP Gritstone Bio, Inc. Transaction History

Gsa Capital Partners LLP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$1.66 - $3.03 $225,947 - $412,422	136,113 New	136,113 $265,000
Q2 2022 Aug 09, 2022	SELL	$1.77 - $4.34 $54,762 - $134,275	-30,939 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$4.03 - $12.19 $124,684 - $377,146	30,939 New	30,939 $127,000
Q4 2021 Feb 14, 2022	SELL	$8.76 - $13.71 $353,054 - $552,554	-40,303 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$6.41 - $13.54 $258,342 - $545,702	40,303 New	40,303 $435,000

1.2M

Ticker GRTS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,006,896
Market Cap $2.19M
Description
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.